PMID- 26766122
OWN - NLM
STAT- MEDLINE
DCOM- 20190705
LR  - 20190705
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 25
IP  - 4
DP  - 2017 Apr
TI  - Comparison of Dual-ISH (DISH) With Fluorescence In Situ Hybridization (FISH) and 
      Correlation With Immunohistochemical Findings for HER2/Neu Status in Breast 
      Carcinoma.
PG  - 231-236
LID - 10.1097/PAI.0000000000000304 [doi]
AB  - INTRODUCTION: The most widely used methods for determination of HER2/neu status 
      in breast carcinoma are immunohistochemistry (IHC) and fluorescence in situ 
      hybridization (FISH). Both techniques are associated with technical and 
      interpretive difficulties. Alternative methods exist including quantitative PCR 
      and the newly developed chromogenic dual in situ hybridization (DISH). METHODS: 
      We evaluated HER2 DISH as an alternative to FISH and report our findings from 101 
      cases. In addition, we correlated HER2 DISH and FISH results with HercepTest and 
      4B5 immunohistochemistry. RESULTS: Eight cases failed FISH analysis and none 
      failed DISH analysis. A 95% (88/93) concordance was found between DISH and FISH 
      for all cases in the series. When only 2+ IHC cases were evaluated, the 
      concordance was 94% for DISH and FISH. Using the 2013 ASCO/CAP recommendations, 
      none of the tested cases were equivocal by FISH or DISH despite 66% of cases 
      being 2+ by HercepTest and 32% by the 4B5 antibody. COMMENT: Our study, which 
      utilizes a majority of IHC equivocal cases, demonstrates that HER2 FISH and DISH 
      are concordant methodologies. HER2 DISH is therefore an acceptable alternative to 
      FISH.
FAU - Layfield, Lester J
AU  - Layfield LJ
AD  - *Department of Pathology and Anatomical Sciences, University of Missouri, 
      Columbia, MO daggerARUP Laboratories, Salt Lake City, UT double daggerVentana Medical Systems, 
      Tucson, AZ.
FAU - Wallander, Michelle L
AU  - Wallander ML
FAU - Tripp, Sheryl R
AU  - Tripp SR
FAU - Redpath, Stella
AU  - Redpath S
FAU - Banks, Peter M
AU  - Banks PM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*diagnosis/pathology
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Receptor, ErbB-2/metabolism
MH  - Reproducibility of Results
EDAT- 2016/01/15 06:00
MHDA- 2019/07/06 06:00
CRDT- 2016/01/15 06:00
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2019/07/06 06:00 [medline]
PHST- 2016/01/15 06:00 [entrez]
AID - 10.1097/PAI.0000000000000304 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2017 Apr;25(4):231-236. doi: 
      10.1097/PAI.0000000000000304.